A study demonstrated that RECQL4 inhibition in prostate cancer cells led to significant reduction in invasive growth in vitro and tumorigenic potential in vivo (Su et al., 2010; Mo et al., 2018). The gene discussed is RECQL4; the disease is prostate carcinoma.